Thottathil Gopan, MD
Endocrinology, Diabetes & Metabolism · Munster, INNPI 1023148939
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 140 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 18.5% — the pattern of someone who eats at a lot of different presentations.
Across 140 payments — averaging $54.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Insulet Corporation$925
- Novo Nordisk$903
- Abbott$597
- Amgen$566
- Medtronic$418
- plus $3K from 26 others
What the payments were for
- Food & beverage$7,659100%
- Education$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 25 | $1,418 |
| Insulet Corporation | 15 | $925 |
| Novo Nordisk | 15 | $903 |
| Abbott | 7 | $597 |
| Amgen(2 entities) | 5 | $566 |
| Medtronic(2 entities) | 4 | $418 |
| Dexcom, Inc. | 10 | $367 |
| Tandem Diabetes Care, Inc. | 2 | $264 |
| BETA Bionics, Inc. | 3 | $260 |
| Madrigal Pharmaceuticals | 2 | $239 |
| Sanofi-aventis U.S. LLC | 7 | $199 |
| Xeris Pharmaceuticals, Inc. | 2 | $191 |
| Boehringer Ingelheim | 4 | $155 |
| Mannkind Corporation | 8 | $141 |
| Sequel Med Tech, LLC | 1 | $134 |
| Ascendis Pharma Endocrinology Inc | 1 | $125 |
| Cequr Corporation | 1 | $117 |
| Lilly USA, LLC | 1 | $108 |
| Johnson & Johnson | 1 | $100 |
| Endo Pharmaceuticals Inc. | 4 | $79 |
| Shire North American Group Inc | 4 | $64 |
| AbbVie | 3 | $62 |
| Antares Pharma, Inc. | 3 | $47 |
| Amarin Pharma, Inc. | 2 | $36 |
| IBSA Pharma Inc. | 2 | $34 |
| Eisai Inc. | 2 | $26 |
| Ascensia Diabetes Care US Inc. | 1 | $22 |
| BD | 1 | $21 |
| UCB, Inc. | 1 | $20 |
| Vivus LLC | 1 | $19 |
| Ipsen Biopharmaceuticals, Inc | 1 | $12 |
| Lifescan, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omnipod$625
- iLet Bionic Pancreas$408
- FREESTYLE LIBRE 3$392
- INPEN SMART INSULIN DELIVERY SYSTEM$303
- TEPEZZA$269
- t:slim X2 Insulin Pump with Control-IQ$264
- FARXIGA$249
- Wegovy$241
- RYBELSUS$241
- REZDIFFRA$239
- iLet Insulin Infusion Kit Inset$136
- iLet Insulin Infusion Kit Contact Detach$136
- TWIIST$134
- Yorvipath$125
- EVENITY$119
- CeQur Simplicity$117
- Ozempic$114
- JARDIANCE$114
- MOUNJARO$108
- MINIMED 780G$104
How this compares
$7,679 in reported general payments places this provider in the 75th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.
See all endocrinology, diabetes & metabolism providers in Indiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 488 | $603,029 |
| JardianceEmpagliflozin | 211 | $212,255 |
| MounjaroTirzepatide | 154 | $179,641 |
| TrulicityDulaglutide | 81 | $94,192 |
| FarxigaDapagliflozin Propanediol | 98 | $89,222 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 118 | $77,495 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 42 | $50,608 |
| Humalog Kwikpen U-200Insulin Lispro | 27 | $43,587 |
| Tresiba Flextouch U-200Insulin Degludec | 24 | $43,369 |
| Tresiba Flextouch U-100Insulin Degludec | 66 | $42,516 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 22 | $42,282 |
| Humalog Kwikpen U-100Insulin Lispro | 125 | $41,334 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 49 | $36,607 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 47 | $26,877 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 44 | $26,391 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Fiasp, Novolog | $903 | $612,524510 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $108 | $287,046285 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $155 | $241,008239 claims |
| AstraZenecaFarxiga | $1,418 | $89,22298 claims |
| AbbVieSynthroid | $62 | $19,754259 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $199 | $17,99029 claims |
| IBSA Pharma Inc.Tirosint | $34 | $4,27922 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.
Other endocrinology, diabetes & metabolism in Munster
- Sana MeahMunster$12K
- Nabeel JabriMunster$11K
- Maali MilhemMunster$5K
- Milli GuptaMunster$4K
- Nirmal NairMunster$3K
- Ali Al KhazaaliMunster$3K
- Isaiah PittmanTerre Haute$1.5M
- Ernest AsamoahIndianapolis$959K
- Erica KretchmanRichmond$609K
- Emily VeenemanSeymour$583K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.